European Journalists' Prize 2008 announced by Bayer HealthCare

Bayer AGScrupulously researched articles dealing with a topic from the worlds of medicine or health care - articles written in a critical, comprehensible, yet objective manner - have an excellent chance of winning the 2008 European Journalists' Prize. The award, which is sponsored by Bayer HealthCare AG, Leverkusen/Germany, is endowed with EUR 7,500.

Journalists may submit their applications by January 31, 2009 to the business address of the Association of German Medical Journalists (Verband Deutscher Medizinjournalisten), Chemnitzer Str. 21, D-70597 Stuttgart, www.journalistenvereinigung.de in accordance with the criteria outlined in the association's statutes, or request the statutes directly from this address. This information can also be viewed on the Internet press pages of Bayer HealthCare: www.viva.vita.bayerhealthcare.com

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

About the Association of German Medical Journalists
The Association of German Medical Journalists [Verband Deutscher Medizinjournalisten, VDMJ] is an umbrella organization comprising the following independent member Associations

  • Arbeitskreis Medizinpublizisten/Klub der Wissenschaftsjournalisten e. V.
  • Kollegium der Medizinjournalisten
  • Vereinigung der Medizinischen Fach- und Standespresse e. V.

The purpose of the VDMJ is to maintain and promote standards in medical journalism. The VDMJ is devoted exclusively and directly to charitable purposes as defined in the regulations of the German Tax Code.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...